Global Biopolar Disorder Therapeutics Market 2015-2019

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Understanding the disorder
Types of bipolar disorder
Causes
Signs and symptoms
Management
Self-help
Epidemiology

PART 06: Pipeline analysis
ITI-007
FK949E
PROCYCLOX
RP5603
CNV1061436
LY2979165
DP-VPA
SKL-PSY
PGW-5
DLP-114
DLP-115
Small molecule targeting GPR78

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Market segmentation by drug class
Mood stabilizers
Anticonvulsants
Atypical antipsychotics
Antidepressant drugs
Anti-anxiety drugs

PART 09: Market segmentation by mechanism of action
Selective serotonin reuptake inhibitors
Serotonin-norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Benzodiazepines
Beta blockers
Others

PART 10: Geographical segmentation
Global bipolar disorder therapeutics market by geographical segmentation 2014-2019
Bipolar disorder therapeutics market in Americas
Bipolar disorder therapeutics market in EMEA
Bipolar disorder therapeutics market in APAC

PART 11: Market drivers
Increase in prevalence of bipolar disorder
High unmet need
Increase in R&D

PART 12: Impact of drivers

PART 13: Market challenges
Use of alternative therapies
Lack of availability of standard diagnostic methods
Limited awareness of disease
Increase in patent expiries

PART 14: Impact of drivers and challenges

PART 15: Market trends
Rise in public awareness
Patient assistance programs
Strategic alliances

PART 16: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 17: Key vendor analysis
Allergan
AstraZeneca
BMS
Eli Lilly
GSK
Janssen Pharmaceuticals

PART 18: Appendix
List of abbreviatios

PART 19: Explore Technavio

Exhibit 01: Product offerings
Exhibit 02: Signs and symptoms of bipolar disorder
Exhibit 03: Signs and symptoms of mania
Exhibit 04: Signs and symptoms of depression
Exhibit 05: Treatment options for bipolar disorder
Exhibit 06: Medications for treating bipolar disorder
Exhibit 07: Global bipolar disorder therapeutics market: Pipeline portfolio
Exhibit 08: Global bipolar disorder therapeutics market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global bipolar disorder therapeutics market by drug class
Exhibit 11: Global bipolar disorder therapeutics market segment by geography 2014
Exhibit 12: Bipolar disorder therapeutics market revenue by geography 2014-2014 ($ millions)
Exhibit 13: Bipolar disorder therapeutics market in Americas 2014-2019 ($ millions)
Exhibit 14: Bipolar disorder therapeutics market in EMEA 2014-2019 ($ millions)
Exhibit 15: Bipolar disorder therapeutics market in APAC 2014-2019 ($ millions)
Exhibit 16: Impact of drivers
Exhibit 11: Common disorders that co-exist with bipolar disorder
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Market share analysis of global bipolar disorder therapeutics market 2014
Exhibit 19: YoY growth rate of major bipolar disorder drugs 2014-2019 ($ millions)
Exhibit 20: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Abilify 2011-2014 ($ millions)
Exhibit 21: Bristol-Myers Squibb: Percentage share of Abilify in US and non-US region based on revenue 2014
Exhibit 22: Bristol-Myers Squibb: Key takeaways
Exhibit 23: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel XR 2011-2014 ($ millions)
Exhibit 24: AstraZeneca: Revenue generated from sales of Seroquel XR by region 2014 ($ millions)
Exhibit 25: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel IR 2011-2014 ($ millions)
Exhibit 26: AstraZeneca: Key takeaways
Exhibit 27: Janssen Pharmaceuticals: YoY growth and revenue generated from net product sales of Risperdal Consta 2011-2014 ($ millions)
Exhibit 28: Janssen Pharmaceuticals: Key takeaways
Exhibit 29: Eli Lilly: YoY growth and revenue generated from net product sales of Zyprexa 2011-2014 ($ millions)
Exhibit 30: Eli Lilly: Key takeaways
Exhibit 31: GlaxoSmithKline: YoY growth and revenue generated from net product sales of Lamictal 2011-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: Revenue generated from sales of Lamictal by region 2014 ($ millions)
Exhibit 33: GlaxoSmithKline: Key takeaways
Exhibit 34: Allergan: Key takeaways
Exhibit 35: Allergan: Business segmentation by product revenue 2014
Exhibit 36: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 37: Allergan: Geographical segmentation by revenue 2014
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: BMS: Segmentation by revenue 2014
Exhibit 42: BMS: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 43: BMS: Geographical segmentation by revenue 2014
Exhibit 44: Lilly: Business segmentation by revenue 2014
Exhibit 45: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 46: Eli Lilly: Geographical segmentation by revenue 2014
Exhibit 47: GSK: Business segmentation by revenue 2014
Exhibit 48: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 49: GSK: Geographical segmentation by revenue 2014
Exhibit 50: Janssen Pharmaceuticals: Key therapeutic areas

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.